GlassScriptPhysician profile
Paul Gerardi
NPI 1629044201
$10,842.01
in general payments reported to CMS, 2019-2025
29 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $794 · 2021: $1,055 · 2022: $1,279 · 2023: $2,096 · 2024: $1,897 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,877.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,957.60 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $1,580.60 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,357.61 | 2019-2024 | Brilinta, Farxiga, Lokelma |
| Abbott Laboratories | $876.84 | 2019-2025 | Jot Dx, Aveir, Merlin@Home |
| Biotronik INC. | $694.01 | 2019-2024 | Biomonitor, Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $629.20 | 2019-2025 | Leqvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $593.75 | 2019-2025 | Lifevest |
| Janssen Scientific Affairs, LLC | $545.77 | 2021-2024 | Xarelto |
| Medtronic, INC. | $368.17 | 2023-2025 | Linq II, Micra |
| E.R. Squibb & Sons, L.L.C. | $231.46 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $207.46 | 2019 | |
| Merck Sharp & Dohme LLC | $190.75 | 2023-2024 | Verquvo |
| Bridgebio Pharma, INC. | $170.62 | 2025 | Attruby |
| Pfizer INC. | $154.77 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $153.10 | 2019-2023 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $147.46 | 2019 | |
| Inspire Medical Systems, INC. | $144.85 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $142.92 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $126.86 | 2023-2025 | Opsumit |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Baxter Healthcare | $81.79 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $70.27 | 2019 | |
| Abiomed | $67.25 | 2023-2025 | Impella |
| Novo Nordisk INC | $59.04 | 2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $58.48 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $39.26 | 2019 | |
| Philips North America LLC | $29.54 | 2024 | (Am5) Lead Management |
| Amarin Pharma, INC. | $23.39 | 2020 | |
| Allergan, INC. | $14.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gerardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.